Scholarlink

Background <p>Epithelial ovarian cancer (EOC) is the most common type of ovarian cancer, with high mortality and recurrence rates related to chemoresistance. The receptor of GnRH type II (GnRHR-II) is a more potent receptor of GnRH that may regulate proliferative capacity in peripheral tissues. Thus, it has the potential to serve as a novel therapy for malignancy. This study aimed to examine the clinicopathological profiles of epithelial ovarian cancer with GnRHR-II expression as well as the possible correlation between GnRHR-II and proliferative activity.</p> Methods <p>We performed a cross-sectional study that included 30 epithelial ovarian cancer tissues embedded in a tissue microarray (TMA). The expression levels of GnRHR-II and Ki-67 were examined using immunohistochemistry and measured automatically using the ImageJ software. The association between GnRHR-II and Ki-67 expression levels was statistically tested. The correlation between GnRHR-II and Ki-67 expression was analyzed using Pearson’s correlation, whereas the expression of GnRHR-II and Ki-67 in various clinicopathological conditions was analyzed using an unpaired t-test.</p> Results <p>The mean age of epithelial ovarian cancer patients in this study was 51.87 ± 9.96&#xa0;years. The mean H-Score of GnRHR-II was 62.52 + 28.96, while the mean H-Score of Ki-67 was 123.68 ± 57.72. We found that higher GnRHR-II expression was associated with a more advanced stage, lymph node metastases, and larger tumor size &gt; T2 (<i>p</i> = 0.002, <i>p</i> = 0.035, <i>p</i> = 0.007, and <i>p</i> = 0.043, respectively). Interestingly, the expression levels of both GnRHR-II and Ki-67 were higher in the endometrioid type (<i>p</i> = 0.043 and <i>p</i> = 0.025, respectively), indicating the importance of this receptor in this histotype. However, the correlation between these two proteins was not statistically significant (<i>p</i> = 0.610).</p> Conclusion <p>GnRHR-II expression was higher in patients with worse clinicopathological profiles, including more advanced stage, lymph node metastases, and larger tumor size. These results indicate that GnRHR-II may play an important role in ovarian cancer progression. Our findings broaden the potential of GnRHR-II as a novel therapeutic candidate for ovarian cancer treatment.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Clinicopathological Profiles and Proliferative Activity of GnRH Receptor Type II Expressing Ovarian Cancer

  • 期刊论文

  • 发表日期：

    2025年2月22日

查看全文
  • Agil Wahyu Wicaksono,
  • Nungki Anggorowati,
  • Ardhanu Kusumanto,
  • Andi Kurniadi,
  • Muhammad Ary Zucha

摘要

Background

Epithelial ovarian cancer (EOC) is the most common type of ovarian cancer, with high mortality and recurrence rates related to chemoresistance. The receptor of GnRH type II (GnRHR-II) is a more potent receptor of GnRH that may regulate proliferative capacity in peripheral tissues. Thus, it has the potential to serve as a novel therapy for malignancy. This study aimed to examine the clinicopathological profiles of epithelial ovarian cancer with GnRHR-II expression as well as the possible correlation between GnRHR-II and proliferative activity.

Methods

We performed a cross-sectional study that included 30 epithelial ovarian cancer tissues embedded in a tissue microarray (TMA). The expression levels of GnRHR-II and Ki-67 were examined using immunohistochemistry and measured automatically using the ImageJ software. The association between GnRHR-II and Ki-67 expression levels was statistically tested. The correlation between GnRHR-II and Ki-67 expression was analyzed using Pearson’s correlation, whereas the expression of GnRHR-II and Ki-67 in various clinicopathological conditions was analyzed using an unpaired t-test.

Results

The mean age of epithelial ovarian cancer patients in this study was 51.87 ± 9.96 years. The mean H-Score of GnRHR-II was 62.52 + 28.96, while the mean H-Score of Ki-67 was 123.68 ± 57.72. We found that higher GnRHR-II expression was associated with a more advanced stage, lymph node metastases, and larger tumor size > T2 (p = 0.002, p = 0.035, p = 0.007, and p = 0.043, respectively). Interestingly, the expression levels of both GnRHR-II and Ki-67 were higher in the endometrioid type (p = 0.043 and p = 0.025, respectively), indicating the importance of this receptor in this histotype. However, the correlation between these two proteins was not statistically significant (p = 0.610).

Conclusion

GnRHR-II expression was higher in patients with worse clinicopathological profiles, including more advanced stage, lymph node metastases, and larger tumor size. These results indicate that GnRHR-II may play an important role in ovarian cancer progression. Our findings broaden the potential of GnRHR-II as a novel therapeutic candidate for ovarian cancer treatment.